H Vernon Roohk1, Asad R Zaidi2, Dimple Patel3,4. 1. Department of Surgery (Emeritus), University of California Irvine, Irvine, CA, USA. 2. Epinex Diagnostics, Inc., 14351 Myford Road, Unit J, Tustin, CA, 92780, USA. 3. Epinex Diagnostics, Inc., 14351 Myford Road, Unit J, Tustin, CA, 92780, USA. dimple@epinex.com. 4. Undergraduate Student of Biomedical Engineering, University of California Irvine, Irvine, CA, USA. dimple@epinex.com.
Abstract
AIMS: Abnormal levels of glycated albumin (GA) are associated with the onset of both diabetes and inflammation. Although inflammation has long been associated with diabetes, this article aims to explore the underlying mechanisms of this relationship as it pertains to the role of GA. METHODS: We have reviewed 52 research articles since the year 2000. Common search terms used were "(inflammatory mediator) and GA" or "inflammation and GA". The findings have been organized according to diabetic complications with respect to the interactions of GA and inflammatory mediators. Glycated albumin and specific inflammatory mediators have been reported to play various roles in the pathogenesis of insulin resistance, atherosclerosis, coronary artery disease, retinopathy, and nephropathy. In the case of nephropathy and recently retinopathy, there is considerable evidence for GA in concert with inflammation playing a direct role in organ pathology. There is copious literature detailing GA's involvement in stimulating inflammatory markers and certain pro-inflammatory cytokines. A recent clinical study has shown GA to be a marker for inflammation in non-diabetic rheumatoid arthritis patients with the significance of standard inflammatory markers. CONCLUSIONS: The clinical utility of GA measurement may likely reside in its versatility as both a mediator of inflammation as well as a marker to track hyperglycemia and other diabetes complications. Further understanding of the role GA plays in glycemic and inflammatory diseases could lead to its acceptance as an independent bio-inflammatory marker.
AIMS: Abnormal levels of glycated albumin (GA) are associated with the onset of both diabetes and inflammation. Although inflammation has long been associated with diabetes, this article aims to explore the underlying mechanisms of this relationship as it pertains to the role of GA. METHODS: We have reviewed 52 research articles since the year 2000. Common search terms used were "(inflammatory mediator) and GA" or "inflammation and GA". The findings have been organized according to diabetic complications with respect to the interactions of GA and inflammatory mediators. Glycated albumin and specific inflammatory mediators have been reported to play various roles in the pathogenesis of insulin resistance, atherosclerosis, coronary artery disease, retinopathy, and nephropathy. In the case of nephropathy and recently retinopathy, there is considerable evidence for GA in concert with inflammation playing a direct role in organ pathology. There is copious literature detailing GA's involvement in stimulating inflammatory markers and certain pro-inflammatory cytokines. A recent clinical study has shown GA to be a marker for inflammation in non-diabetic rheumatoid arthritispatients with the significance of standard inflammatory markers. CONCLUSIONS: The clinical utility of GA measurement may likely reside in its versatility as both a mediator of inflammation as well as a marker to track hyperglycemia and other diabetes complications. Further understanding of the role GA plays in glycemic and inflammatory diseases could lead to its acceptance as an independent bio-inflammatory marker.
Entities:
Keywords:
Glycated albumin; Glycated albumin point-of-care test; Inflammation; Inflammatory marker
Authors: Sydney C W Tang; Joseph C K Leung; Loretta Y Y Chan; Anita W L Tsang; Kar Neng Lai Journal: J Am Soc Nephrol Date: 2006-05-10 Impact factor: 10.121
Authors: Kate S Collison; Ranjit S Parhar; Soad S Saleh; Brian F Meyer; Aaron A Kwaasi; Muhammad M Hammami; Ann Marie Schmidt; David M Stern; Futwan A Al-Mohanna Journal: J Leukoc Biol Date: 2002-03 Impact factor: 4.962
Authors: Jeanethe Anguizola; Ryan Matsuda; Omar S Barnaby; K S Hoy; Chunling Wa; Erin DeBolt; Michelle Koke; David S Hage Journal: Clin Chim Acta Date: 2013-07-24 Impact factor: 3.786
Authors: Michael Bergman; Muhammad Abdul-Ghani; Ralph A DeFronzo; Melania Manco; Giorgio Sesti; Teresa Vanessa Fiorentino; Antonio Ceriello; Mary Rhee; Lawrence S Phillips; Stephanie Chung; Celeste Cravalho; Ram Jagannathan; Louis Monnier; Claude Colette; David Owens; Cristina Bianchi; Stefano Del Prato; Mariana P Monteiro; João Sérgio Neves; Jose Luiz Medina; Maria Paula Macedo; Rogério Tavares Ribeiro; João Filipe Raposo; Brenda Dorcely; Nouran Ibrahim; Martin Buysschaert Journal: Diabetes Res Clin Pract Date: 2020-06-01 Impact factor: 5.602
Authors: Michal Pyzik; Kine M K Sand; Jonathan J Hubbard; Jan Terje Andersen; Inger Sandlie; Richard S Blumberg Journal: Front Immunol Date: 2019-07-10 Impact factor: 7.561